Kimberly-Clark formally seeks EU antitrust approval for Kenvue deal, moving the regulatory clock forward.

What happened

Kimberly-Clark has filed a notification with the European Commission seeking approval for its $40 billion acquisition of Kenvue, the Tylenol maker, according to Reuters. This filing initiates the EU merger review, which is one of the remaining foreign regulatory approvals needed before the deal can close, targeted for 2H26. Kenvue's latest 10-K already highlighted foreign approvals as the primary gating item after U.S. HSR clearance and shareholder votes. The EU process could take up to several months and may involve a Phase II investigation if the Commission identifies antitrust concerns, particularly in overlapping consumer health categories. While the filing itself is a routine step, it does not eliminate the risk that EU regulators may demand divestitures or other remedies, which could delay closing or reduce synergies.

Implication

This development reinforces the base-case scenario that foreign approvals will progress, but the probability-weighted value remains dependent on the absence of material remedies. If the EU clears the deal swiftly and unconditionally, the spread should tighten toward the deal value, supporting KVUE's price near $19. However, a Phase II investigation or demands for divestitures could pressure the stock toward the bear-case $14 implied value, as integration synergies and closing timeline would be jeopardized. Given the EU's history of scrutinizing consumer health overlaps, we assign a moderate probability of remedial conditions, and we maintain our 'Potential Buy' rating with an attractive entry below $16.50 and a trim above $20.00. We will monitor the EU's decision within the next few months and adjust our view if any remedies are proposed.

Thesis delta

The filing does not change the core thesis that KVUE is a merger-close instrument with remaining foreign approval and litigation risk. It confirms that the process is advancing as expected, but the next critical checkpoint is the EU's phase-one decision and whether it opens a Phase II or requests commitments. We leave our scenario probabilities unchanged, with the base case at 55% and an implied value of $19.